JW (CAYMAN) THERAPEUTICS CO. LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.26 HKD | -2.16% |
|
-8.13% | 0.00% |
| Mar. 20 | JW (Cayman) Therapeutics Shrinks Loss in Fiscal 2023 | MT |
| Mar. 20 | JW Therapeutics Co. Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 268M 37.02M 289M | Sales 2025 * | 418M 57.69M 451M | Capitalization | 846M 117M 912M |
|---|---|---|---|---|---|
| Net income 2024 * | -597M -82.44M -644M | Net income 2025 * | -513M -70.84M -553M | EV / Sales 2024 * | 1.99 x |
| Net cash position 2024 * | 313M 43.27M 338M | Net Debt 2025 * | 111M 15.27M 119M | EV / Sales 2025 * | 2.29 x |
| P/E ratio 2024 * |
-1.44
x | P/E ratio 2025 * |
-1.67
x | Employees | 398 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.29% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.16% | ||
| 1 week | -8.13% | ||
| Current month | +26.26% | ||
| 1 month | +29.14% | ||
| 3 months | +13.00% | ||
| 6 months | -13.08% |
1 week
2.16
2.60
1 month
1.692.68
Current year
1.582.68
1 year
1.583.49
3 years
1.5834.75
5 years
1.5852.80
10 years
1.5852.80
| Managers | Title | Age | Since |
|---|---|---|---|
Yi Ping Li
CEO | Chief Executive Officer | 59 | 17-09-05 |
| Chief Tech/Sci/R&D Officer | 43 | 22-01-09 | |
Mark Gilbert
CTO | Chief Tech/Sci/R&D Officer | 63 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Debra Yu
BRD | Director/Board Member | 59 | 23-02-28 |
Cheng Liu
BRD | Director/Board Member | 57 | 20-06-29 |
Yi Ping Li
CEO | Chief Executive Officer | 59 | 17-09-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.70% | 4 M€ | -27.92% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 2.26 | -2.16% | 227 000 |
| 24-05-23 | 2.31 | -1.70% | 127,500 |
| 24-05-22 | 2.35 | +3.07% | 165,500 |
| 24-05-21 | 2.28 | -5.79% | 534,578 |
| 24-05-20 | 2.42 | -5.10% | 458,500 |
Delayed Quote Hong Kong S.E., May 24, 2024 at 04:08 am EDT
More quotes
JW Cayman Therapeutics Co Ltd is a China-based company mainly engaged in the clinical and pre-clinical stage cell therapy. The Company is focuses on developing cell therapies for the China market to transform the treatment of cancer for Chinese patients. Through its subsidiary, it has built an integrated platform focused on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its main product candidate, relmacabtagene autoleucel (relma-cel), is an autologous anti-CD19 CAR-T therapy for relapsed or refractory (r/r) B-cell lymphoma. The Company mainly conducts its businesses in the China market.
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.095
CNY
Average target price
2.508
CNY
Spread / Average Target
+19.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 119M | |
| +12.20% | 116B | |
| +12.24% | 106B | |
| -8.31% | 23.89B | |
| -1.69% | 21.58B | |
| -10.60% | 18.96B | |
| -41.25% | 16.96B | |
| -15.46% | 16.33B | |
| +6.19% | 14.14B | |
| +28.57% | 12.02B |
- Stock Market
- Equities
- 2126 Stock
